Results 181 to 190 of about 26,895 (263)

Continuous glucose monitoring–guided management of capivasertib‐associated hyperglycemia: A case series of three patients

Journal of Diabetes Investigation, EarlyView.
Continuous glucose monitoring (CGM) visualized cyclic glycemic fluctuations associated with the 4‐days‐on/3‐days‐off capivasertib schedule. Compared with off‐treatment days, dosing days showed higher mean sensor glucose, greater coefficient of variation (CV), more time above 250 mg/dL, and lower time in range (TIR; 70–180 mg/dL).
Hiroki Okumura, Ryotaro Bouchi, Kenju Ando, Hannah Mizuno, Hirofumi Sugimoto, Kotaro Umamoto, Noriko Kodani, Noriko Ihana‐Sugiyama, Kazuo Izumi, Mitsuru Ohsugi, Kohjiro Ueki, Akihiko Shimomura, Chikako Shimizu, Akiyo Tanabe   +13 more
wiley   +1 more source

Diabetic remission in a newly diagnosed diabetic cat treated with SGLT2 inhibitor. [PDF]

JFMS Open Rep
Lodarski F, Benchekroun G, Cervone M.
europepmc   +1 more source

Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune‐mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital‐based claims database

Journal of Diabetes Investigation, EarlyView.
In this target trial emulation of patients with immune‐mediated inflammatory diseases and type 2 diabetes, SGLT2 inhibitor initiation was not associated with a clear increase in UTI risk versus metformin, including across immunosuppressive therapy strata.
Hiroshi Tsushima, Nobuyuki Yajima, Takashi Nomiyama, Ryoko Sakai, Hisashi Noma, Akira Katagiri, Naoto Tamura   +6 more
wiley   +1 more source

SGLT2 inhibitor therapy in diabetic cats: first clinical experiences with non-ideal candidates. [PDF]

J Feline Med Surg
Vanneste A, Van Heuckelom E, Vannieuwenhuyse D, De Voogt C, Daminet S.   +4 more
europepmc   +1 more source

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

Journal of Diabetes Investigation, EarlyView.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani, Nobuyuki Banba, Shoya Ono, Tomoki Turumi, Megumi Hoshiai, Takushi Sugiyama, Takashi Tomoe, Hajime Tamiya, Naoyuki Otani, Hiroyuki Sugimura, Hidekazu Ikemiyagi, Yusuke Ohya, Koji Yokokawa, Shinichiro Ueda, Yoshimasa Aso, Yasuhiro Maejima, Takanori Yasu   +16 more
wiley   +1 more source

Impact of Increased SGLT2 Inhibitor Uptake in CKD Management in Denmark: Modeling National Patient Benefits and Cost Savings. [PDF]

Kidney Med
Hangaard Olesen R, Carlson N, Søndergaard J, Freese Ballegaard EL, Borg R, Ehlers LH.   +5 more
europepmc   +1 more source

Association of SGLT2 Inhibitor With Stroke in Type 2 Diabetes With Diabetic Retinopathy: A Multicenter Electronic Health Record Data Study. [PDF]

Diabetes Obes Metab
Chen KE, Wang PC, Lin HA, Lin SF.
europepmc   +1 more source

Effectiveness of tirzepatide in Japanese patients with type 2 diabetes but no obesity: A sub‐analysis of Hokkaido‐TZP study data

Journal of Diabetes Investigation, EarlyView.
Tirzepatide achieved significant HbA1c reduction in Japanese patients with type 2 diabetes without obesity, regardless of baseline BMI. Weight reduction was BMI‐dependent and enhanced by dietary consultations. No patient developed underweight status during the 6‐month observation period.
Tomoe Abe, Fumika Maruyama, Eisuke Nishikawa, Miki Ito, Yukie Miyano, Hiroki Yamagata, Taiga Sasaki, Hidemitsu Sakagami, Akinobu Nakamura, Hiroshi Nomoto, on behalf of the Hokkaido‐TZP Study Group   +10 more
wiley   +1 more source

Age disparities in SGLT2 inhibitor prescription among people with type 2 diabetes: The role of frailty and sex. [PDF]

Diabetes Obes Metab
Yang C, Denig P, Chepulis L, Paul RG, Shin JI, Gansevoort RT, Vart P.   +6 more
europepmc   +1 more source

Monocyte dipeptidyl peptidase 4 activity is associated with urinary albumin excretion in type 2 diabetes

Journal of Diabetes Investigation, EarlyView.
This study examined whether dipeptidyl peptidase 4 (DPP4) characteristics in peripheral blood monocytes relate to renal parameters. Monocyte DPP4 activity was independently associated with urinary albumin excretion in patients with type 2 diabetes, suggesting that monocytes may function as a cellular link between DPP4 and diabetic kidney disease ...
Hideyuki Okuma, Takahiro Tsutsumi, Kyoichiro Tsuchiya   +2 more
wiley   +1 more source